Logo image of XTNT

XTANT MEDICAL HOLDINGS INC (XTNT) Stock Fundamental Analysis

USA - NYSEARCA:XTNT - US98420P3082 - Common Stock

0.782 USD
+0 (+0.26%)
Last: 10/22/2025, 6:40:00 PM
0.799 USD
+0.02 (+2.17%)
After Hours: 10/22/2025, 6:40:00 PM
Fundamental Rating

3

Overall XTNT gets a fundamental rating of 3 out of 10. We evaluated XTNT against 190 industry peers in the Health Care Equipment & Supplies industry. XTNT has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, XTNT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

XTNT had negative earnings in the past year.
In the past year XTNT had a positive cash flow from operations.
In the past 5 years XTNT reported 4 times negative net income.
In the past 5 years XTNT reported 4 times negative operating cash flow.
XTNT Yearly Net Income VS EBIT VS OCF VS FCFXTNT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

XTNT has a better Return On Assets (-4.43%) than 66.32% of its industry peers.
XTNT's Return On Equity of -9.44% is fine compared to the rest of the industry. XTNT outperforms 66.32% of its industry peers.
The Return On Invested Capital of XTNT (0.03%) is better than 65.26% of its industry peers.
Industry RankSector Rank
ROA -4.43%
ROE -9.44%
ROIC 0.03%
ROA(3y)-10.3%
ROA(5y)-11.34%
ROE(3y)-20.61%
ROE(5y)-25.18%
ROIC(3y)N/A
ROIC(5y)N/A
XTNT Yearly ROA, ROE, ROICXTNT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

XTNT's Operating Margin of 0.02% is fine compared to the rest of the industry. XTNT outperforms 65.26% of its industry peers.
XTNT's Gross Margin of 60.16% is fine compared to the rest of the industry. XTNT outperforms 60.53% of its industry peers.
In the last couple of years the Gross Margin of XTNT has declined.
Industry RankSector Rank
OM 0.02%
PM (TTM) N/A
GM 60.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.35%
GM growth 5Y-2.41%
XTNT Yearly Profit, Operating, Gross MarginsXTNT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

3

2. Health

2.1 Basic Checks

XTNT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for XTNT has been increased compared to 1 year ago.
The number of shares outstanding for XTNT has been increased compared to 5 years ago.
XTNT has a worse debt/assets ratio than last year.
XTNT Yearly Shares OutstandingXTNT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
XTNT Yearly Total Debt VS Total AssetsXTNT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

XTNT has an Altman-Z score of -0.51. This is a bad value and indicates that XTNT is not financially healthy and even has some risk of bankruptcy.
XTNT has a Altman-Z score of -0.51. This is comparable to the rest of the industry: XTNT outperforms 41.05% of its industry peers.
XTNT has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
XTNT's Debt to Equity ratio of 0.46 is in line compared to the rest of the industry. XTNT outperforms 45.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Altman-Z -0.51
ROIC/WACC0
WACC8.95%
XTNT Yearly LT Debt VS Equity VS FCFXTNT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

XTNT has a Current Ratio of 2.47. This indicates that XTNT is financially healthy and has no problem in meeting its short term obligations.
XTNT's Current ratio of 2.47 is in line compared to the rest of the industry. XTNT outperforms 50.00% of its industry peers.
XTNT has a Quick Ratio of 1.16. This is a normal value and indicates that XTNT is financially healthy and should not expect problems in meeting its short term obligations.
XTNT has a worse Quick ratio (1.16) than 70.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.47
Quick Ratio 1.16
XTNT Yearly Current Assets VS Current LiabilitesXTNT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

4

3. Growth

3.1 Past

The earnings per share for XTNT have decreased strongly by -100.00% in the last year.
The Revenue has grown by 15.16% in the past year. This is quite good.
The Revenue has been growing by 12.64% on average over the past years. This is quite good.
EPS 1Y (TTM)-100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
Revenue 1Y (TTM)15.16%
Revenue growth 3Y28.5%
Revenue growth 5Y12.64%
Sales Q2Q%18.26%

3.2 Future

XTNT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.30% yearly.
XTNT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.31% yearly.
EPS Next Y108.5%
EPS Next 2Y42.92%
EPS Next 3Y30.31%
EPS Next 5YN/A
Revenue Next Year10.6%
Revenue Next 2Y0.34%
Revenue Next 3Y3.31%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
XTNT Yearly Revenue VS EstimatesXTNT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
XTNT Yearly EPS VS EstimatesXTNT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2023 2024 2025 2026 2027 0 -5 -10 -15 -20

2

4. Valuation

4.1 Price/Earnings Ratio

XTNT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 153.33, which means the current valuation is very expensive for XTNT.
Compared to the rest of the industry, the Price/Forward Earnings ratio of XTNT indicates a somewhat cheap valuation: XTNT is cheaper than 66.32% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of XTNT to the average of the S&P500 Index (23.09), we can say XTNT is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 153.33
XTNT Price Earnings VS Forward Price EarningsXTNT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, XTNT is valued a bit cheaper than the industry average as 71.05% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 30.42
XTNT Per share dataXTNT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as XTNT's earnings are expected to grow with 30.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.92%
EPS Next 3Y30.31%

0

5. Dividend

5.1 Amount

No dividends for XTNT!.
Industry RankSector Rank
Dividend Yield N/A

XTANT MEDICAL HOLDINGS INC

NYSEARCA:XTNT (10/22/2025, 6:40:00 PM)

After market: 0.799 +0.02 (+2.17%)

0.782

+0 (+0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)10-30 2025-10-30/bmo
Inst Owners57.12%
Inst Owner Change0%
Ins Owners14.93%
Ins Owner Change-0.26%
Market Cap109.48M
Revenue(TTM)127.77M
Net Income(TTM)-4581000
Analysts85
Price Target1.79 (128.9%)
Short Float %0.06%
Short Ratio0.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)198.04%
Min EPS beat(2)100%
Max EPS beat(2)296.08%
EPS beat(4)2
Avg EPS beat(4)77.12%
Min EPS beat(4)-56.86%
Max EPS beat(4)296.08%
EPS beat(8)3
Avg EPS beat(8)73.86%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)7.07%
Min Revenue beat(2)3.39%
Max Revenue beat(2)10.74%
Revenue beat(4)2
Avg Revenue beat(4)1.19%
Min Revenue beat(4)-6.52%
Max Revenue beat(4)10.74%
Revenue beat(8)6
Avg Revenue beat(8)5.84%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)150%
EPS NY rev (3m)128.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 153.33
P/S 0.86
P/FCF N/A
P/OCF 72.94
P/B 2.26
P/tB 3.25
EV/EBITDA 30.42
EPS(TTM)-0.04
EYN/A
EPS(NY)0.01
Fwd EY0.65%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.01
OCFY1.37%
SpS0.91
BVpS0.35
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.43%
ROE -9.44%
ROCE 0.04%
ROIC 0.03%
ROICexc 0.03%
ROICexgc 0.04%
OM 0.02%
PM (TTM) N/A
GM 60.16%
FCFM N/A
ROA(3y)-10.3%
ROA(5y)-11.34%
ROE(3y)-20.61%
ROE(5y)-25.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.35%
GM growth 5Y-2.41%
F-Score5
Asset Turnover1.23
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF N/A
Debt/EBITDA 4.97
Cap/Depr 97.07%
Cap/Sales 3.39%
Interest Coverage 0.01
Cash Conversion 33.42%
Profit Quality N/A
Current Ratio 2.47
Quick Ratio 1.16
Altman-Z -0.51
F-Score5
WACC8.95%
ROIC/WACC0
Cap/Depr(3y)93.26%
Cap/Depr(5y)102.58%
Cap/Sales(3y)2.72%
Cap/Sales(5y)2.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
EPS Next Y108.5%
EPS Next 2Y42.92%
EPS Next 3Y30.31%
EPS Next 5YN/A
Revenue 1Y (TTM)15.16%
Revenue growth 3Y28.5%
Revenue growth 5Y12.64%
Sales Q2Q%18.26%
Revenue Next Year10.6%
Revenue Next 2Y0.34%
Revenue Next 3Y3.31%
Revenue Next 5YN/A
EBIT growth 1Y100.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year230.8%
EBIT Next 3Y49%
EBIT Next 5YN/A
FCF growth 1Y74.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y116.46%
OCF growth 3YN/A
OCF growth 5YN/A